Bevacizumab Plus Chemo Extends Survival in Metastatic Cervical Cancer

Adding bevacizumab to chemotherapy extended survival by about 4 months beyond the survival achieved with chemotherapy alone in chemotherapy-naïve patients with persistent, recurrent, or metastatic cervical...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news